Cutler Group’s KalVista Pharmaceuticals KALV Stock Holding History

Cutler Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-300	Closed	-$3K	–	5967
2020 Q4	$3K	Buy	+300	New	+$5.14K	﹤0.01%	3966

Other funds holding KALV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cutler Group's KALV Position: Q4 2021 in Review

Cutler Group sold out of KalVista Pharmaceuticals (KALV) in Q4 2021, closing a stake of 100 shares — an estimated $1K sold.

Cutler Group first reported a position in KALV in Q4 2020 and held it in 2 quarters. The position peaked at $13K in Q4 2020. 97 funds tracked by Wall St. Rank hold KALV as of Q4 2021.

Cutler Group reported no remaining KalVista Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 100 KalVista Pharmaceuticals shares in Q4 2021, an estimated $1K.
Cutler Group first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Cutler Group's KalVista Pharmaceuticals position peaked at $13K in Q4 2020.
97 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.